

Clearbridge's Subsidiary Secures New Funds to Accelerate the Commercialisation of its Computational Imaging Microscopy Technology

- *Clearbridge Biophotonics' patented computational imaging microscopy technology being developed to target unmet needs in the area of live cells imaging for drug discovery and biomedical research*
- *Global Live Cell Imaging Market is expected to reach US\$2.9 billion by 2023*
- *Clearbridge Biophotonics to issue S\$2.0 million in convertible bonds for its commercialisation activities*
- *SEEDS Capital Pte. Ltd., the investment arm of Enterprise Singapore, a government agency championing enterprise development, will subscribe for S\$1.0 million of the convertible bonds*

SINGAPORE, 25 March 2019 – Integrated healthcare company Clearbridge Health Limited ("Clearbridge" or the "Company" and together with its subsidiaries, the "Group") ("明策集團"), is pleased to announce that its subsidiary, Clearbridge Biophotonics Pte. Ltd. ("CBBP"), has secured new funds to accelerate the commercialisation activities of its computational imaging microscopy technology that is powered by in-house proprietary algorithms.

SEEDS Capital Pte. Ltd., the investment arm of Enterprise Singapore, will subscribe for S\$1.0 million of the convertible bonds, while Clearbridge's wholly-owned subsidiary, Clearbridge BSA Pte. Ltd., will convert existing loans to CBBP for S\$1.0 million of the convertible bonds.

Following completion of its prototype system for live cell imaging, CBBP has undertaken co-development agreements with leading biopharmaceutical companies and academic institutions to demonstrate and validate its computational imaging technology in the live cell imaging field.

Building on the progress in its development activities in recent years, CBBP has developed imaging devices that specialise in live cell imaging to target the unmet needs in live cell imaging for drug discovery and biomedical research.

Potential of CBBP's Algorithm-Powered Microscopy Technology

According to the report "Live Cell Imaging Market by Product (Instruments, Consumables, Software, Services), Application (Cell Biology, Stem Cells, Drug Discovery), End User (Pharmaceutical & Biotechnology Companies, Research Institutes) - Global Forecasts to 2023", published by MarketsandMarkets™, the Live Cell Imaging Market is expected to reach US\$2.9 billion by 2023.



Positioned to disrupt the live cell imaging market with its algorithm-powered microscopy technology, CBBP's imaging devices offers users the ability to perform high throughput, concurrent imaging of multiple cell responses.

As compared to the existing systems and techniques in this specialised field, CBBP's innovative microscopy technology and imaging devices provide pharmaceutical companies and researchers several new value propositions, including novel insights in drug discovery and development as well as cost and time saving.

In addition, CBBP's algorithm-powered microscopy technology can enable other imaging applications (e.g. AI enabled digital pathology), thereby creating new solutions to aid medical research and treatment in other areas.

Commenting on this latest funding round by CBBP, **Mr Jeremy Yee (余斌), Executive Director and Chief Executive Officer of Clearbridge**, said, *"Live cell imaging is a vital analytical tool used to study cancer. This niche market is growing rapidly with the rising incidence of cancer and accelerated drug development efforts to combat cancer."*

There are huge market opportunities in this specialised area and CBBP's unique microscopy technology is attracting investor interest from US venture capital firms specializing in life sciences investments.

Concurrently, we are excited about the potential to commercialise CBBP's imaging devices that will clearly differentiate it from the rest currently on the market."

– END –

Issued on behalf of Clearbridge Health Limited by 8PR Asia Pte Ltd.

Media & Investor Contacts:



Mr. Alex TAN
Mobile: +65 9451 5252
Email: alex.tan@8prasia.com

About Clearbridge Health Limited

(Bloomberg Code: CBH:SP / Reuters Code: CLEA.SI / SGX Code: 1H3)

Clearbridge Health Limited is a healthcare company with a focus on the delivery of precision medicine in Asia. Its business comprises laboratory testing services, medical clinics/centres and strategic equity participation in complementary precision medical technology companies.

Through the delivery of precision medicine in Asia, it seeks to empower clinicians and healthcare professionals to make more reliable and accurate diagnoses, provide insights to



disease management, and tailor personalised prevention and timely treatment programmes for patients. It is executing the above strategies by way of primary healthcare and healthcare systems that reside in nexus of high demand.

For more information, please visit us at www.clearbridgehealth.com.

This press release has been prepared by the Company and its contents have been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "SGX-ST").

The Sponsor has not independently verified the contents of this press release. This press release has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.